IP Library Granted Patent US 10,174,365
Granted Patent B2
US 10,174,365 · App. 14/006,089 · Granted Jan 8, 2019

Method of analysing a blood sample of a subject for the presence of a disease marker

Inventors: Thomas Wurdinger (Amsterdam, NL); Rolf Jonas Nilsson (Amsterdam, NL)
Assignees: STICHTING VU-VUMC; VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
C12Q1/6834C12Q1/6886C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,174,365
App. No.
14/006,089
Granted
Jan 8, 2019
Kind
B2
Abstract

The present invention relates to a method of analyzing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analyzing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.

Claims (9)

1. A method of quantifying RNA levels in a blood sample of a subject, said method comprising the steps of:

a) isolating thrombocytes from the blood sample;

b) extracting messenger ribonucleic acid (mRNA) from said thrombocytes to provide an extracted nucleic acid fraction from said thrombocytes;

c) analyzing said extracted nucleic acid fraction by reverse transcribing extracted mRNA into cDNA, quantifying said cDNA to determine the amount of mRNA of at least three genes by conducting an amplification reaction which employs gene specific primers, wherein the at least three genes comprise genes encoding prostate cancer antigen 3, prostate-specific antigen, and epidermal growth factor receptor variant III.

2. The method of claim 1 , wherein the primers for prostate specific antigen comprise SEQ ID NO: 3 and SEQ ID NO: 4.

3. The method of claim 1 , wherein the primers for prostate cancer antigen 3 comprise SEQ ID NO: 5 and SEQ ID NO: 6.

4. The method of claim 1 , wherein the primers for prostate cancer antigen 3 comprise SEQ ID NO: 7 and SEQ ID NO: 8.

5. The method of claim 1 , wherein the primers for epidermal growth factor receptor variant III comprise SEQ ID NO: 9 and SEQ ID NO: 10.

6. The method of claim 1 , wherein the primers for epidermal growth factor receptor variant III comprise SEQ ID NO: 11 and SEQ ID NO: 12.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Apr 19, 2024
From: ACADEMISCH MEDISCH CENTRUM; STICHTING VUMC
To: STICHTING AMSTERDAM UMC
Reel/Frame 067172/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
To: STICHTING VUMC
Reel/Frame 051638/0271 →
DE-MERGER Recorded Jan 28, 2020
From: STICHTING VU-VUMC
To: STICHTING VUMC
Reel/Frame 051719/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2013
From: WURDINGER, THOMAS; NILSSON, ROLF JONAS
To: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG; STICHTING VU-VUMC
Reel/Frame 031695/0886 →
Priority Claims (3)
EP 11158912 · Mar 18, 2011 · regional
EP 11167973 · May 27, 2011 · regional
WO PCT/NL2011/050518 · Jul 15, 2011 · international
Continuity (1)
Related Publication 20140199693A1 · Jul 17, 2014